Baseline Characteristics of Pediatric Patients with Multiple Sclerosis Enrolled in the PARADIGMS Study: A Randomized, Double-Blind Study of Fingolimod versus Interferon-{beta}-1a (P1.347)

Conclusions:Patients enrolled in the PARADIGMS study had a high frequency of relapses and Gd+ lesions early in their course of the disease and the majority were at post-pubertal stage. These characteristics are in line with the previously known pediatric MS cohorts. The recruitment target has been successfully met; however recruitment remains open to enroll additional eligible pre-pubertal patients.Study Supported by: Novartis Pharma AG.Disclosure: Dr. Chitnis received personal compensation for activities with Roche-Genentech and Sanofi-Genzyme. Dr. Chitnis received research support from EMD Serono, Biogen, Novartis and Verily. Dr. Arnold has received personal compensation for activities with Coronado Biosciences, Consortium of Multiple Sclerosis Centers, Eli Lilly, EMD Serono, Genentech, Genzyme, GlaxoSmithKline, MS Forum, NeuroRx Research, Novartis, Opexa Therapeutics, Roche, Merck Serono, S.A. Serono Symposia International Foundation, Teva, the Canadian Institutes of Health Research, and the Multiple Sclerosis Society of Canada. Dr. Arnold holds stock and/or stock options in NeuroRx Research. Dr. Banwell has received personal compensation for activities with Novartis. Dr. Banwell has received personal compensation in an editorial capacity for Multiple Sclerosis and Related Disorders. Dr. Brueck has received personal compensation for activities with Bayer Vital, Biogen, Merck Serono, Teva Pharma, Genzyme, Sanofi Aventis, and Novartis as a lecturer or member of scientific ad...

Source: Neurology - April 17, 2017 Category: Neurology Authors: Chitnis, T., Arnold, D., Banwell, B., Bruck, W., Ghezzi, A., Giovannoni, G., Greenberg, B., Krupp, L., Rostasy, K., Tardieu, M., Waubant, E., Wolinsky, J., Bar-Or, A., Stites, T., Jessop, N., Merschhemke, M. B., Gartner, J. Tags: Pediatric Multiple Sclerosis Source Type: research